Latest news with #opioidaddiction
The Independent
3 days ago
- Business
- The Independent
Drug maker Indivior to delist its shares from London Stock Exchange
Indivior, a pharmaceutical firm specializing in opioid addiction treatments, plans to delist from the London Stock Exchange (LSE) on July 25, following its primary listing move to the US's Nasdaq index last year. The company cites reduced costs and complexity, along with the fact that over 80% of its revenue is generated in the US, as reasons for the delisting. Indivior also noted that liquidity on the Nasdaq now significantly surpasses that of the LSE, with a greater level of trading activity. Indivior 's chairman, David Wheadon, stated that a single primary listing on Nasdaq best reflects the profile of Indivior 's business. Despite Indivior 's exit, the LSE welcomes Valterra Platinum, Anglo American's platinum spin-off, after becoming independent from the mining giant.
Bloomberg
4 days ago
- Business
- Bloomberg
Indivior Plans to Cancel London Listing After Moving Primary to US
Indivior Plc said it plans to cancel its secondary listing in London nearly a year after the drugmaker shifted its primary trading to the US, marking the latest departure from the UK's capital markets. The opioid-addiction therapy maker moved its main listing to New York last year in search of more analyst and investor coverage, but had a rocky start amid guidance cuts. It's planning to ditch the secondary trading it had maintained on the London Stock Exchange to better reflect where its revenues come from and eliminate the cost of the secondary listing, given most of its volume and investors are now in the US, according to a statement.
